Nucleai
Overview
Nucleai is an AI-powered spatial biology platform designed to analyze complex tissue images and extract insights for drug development and diagnostics, primarily in oncology. The platform is intended for use by pharmaceutical companies, biopharmaceutical firms, and clinical research institutions. It aims to support translational research, clinical development, and companion diagnostic development.
- What it does: Nucleai’s technology uses advanced spatial AI methods to analyze and interpret cellular interactions within patient biopsies. It ingests images from various modalities, including H&E, IHC, multiplex immunofluorescence (mIF), and spatial transcriptomics. The platform then conducts spatial analysis to optimize biomarker scoring, determine biomarker prevalence and mechanism of action (MoA), and predict response to therapy.
- Who it is for: The tool is primarily for researchers and clinicians involved in oncology and immunology drug development. This includes professionals in translational pathology, digital pathology, diagnostics, precision medicine, and basic research/academia.
- How it fits a clinical or practice workflow: Nucleai’s platform can integrate with Laboratory Information Management Systems (LIMS) and Laboratory Management Systems (LMS) for real-time data sharing and on-demand AI analysis to augment clinicians’ review of diagnostic pathology cases. It can streamline patient eligibility assessments for clinical trials and assist in developing companion diagnostics. The platform also offers an end-to-end mIF analytics workflow, from image ingest to structured outputs for downstream spatial analysis.
- Notable capabilities: The platform offers automated normalization and cell segmentation across multiple stainers, AI-driven cell typing and marker positivity, and standardized, exportable cell and image-level outputs. It can analyze spatial features to explain the mechanism of action and biological phenomena, and leverage spatial analysis to predict outcomes, genomic status, and protein signatures. Nucleai has also developed a deep learning model to automate spatial proteomics, which is designed to rapidly analyze dozens of protein markers in a single image.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-Driven Spatial Biomarker Analysis
- Multimodal Image Ingestion (H&E, IHC, multiplex immunofluorescence, spatial transcriptomics)
- Advanced Spatial Analysis
- Biomarker Discovery & Validation
- Biomarker Scoring
- Genomic Biomarker Screening
- Mechanism of Action (MoA) Data Enrichment
- Companion Diagnostics Development
- Prediction of Therapy Response
Use Cases
- Powering Drug Development
- Translational Research to Diagnostics
- Clinical Trial Patient Selection
- Optimizing Biomarker Scoring
- Determining Biomarker Prevalence and MoA
- Predicting Response to Therapy
What Physicians Need to Know
Physicians can leverage Nucleai's AI-powered spatial biology platform to gain deeper insights into the tumor microenvironment, enabling more precise patient stratification and personalized treatment strategies, especially for complex oncology cases. The platform's ability to analyze multiplexed samples with high accuracy and integrate various data modalities can aid in identifying patients most likely to respond to specific therapies, thereby optimizing clinical trial participation and improving treatment outcomes.
Nucleai's platform is designed for integration with various imaging modalities (H&E, IHC, multiplex immunofluorescence, spatial transcriptomics) and is agnostic to staining and scanning platforms. They have established partnerships for systems integration with Laboratory Information Management Systems (LIMS) and Laboratory Management Systems (LMS) for real-time data sharing and on-demand AI analysis. Collaborations with digital pathology companies like Proscia aim to integrate Nucleai's predictive biomarker technology into enterprise pathology platforms.
Details
| Category | Drug Discovery & Research, Lab & Diagnostics, Pathology AI |
| Pricing | Unknown |
| Deployment | Cloud-based platform. |
| Mobile App | None |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Unknown |
| SOC 2 | Yes AI-estimated |
| GDPR | Yes AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Gastroenterology, Oncology, Pathology |
What the Web Says
Nucleai is an AI-powered digital pathology company that aims to transform drug development and clinical treatment decisions by providing actionable insights from tissue analysis. Their platform utilizes AI-driven multimodal tissue analysis, spatial biology, and clinical outcomes correlation to deliver reproducible and traceable evidence for pharmaceutical companies. The company's technology helps pathologists process and analyze biopsies for cancer more accurately and quickly, and also assists in identifying biomarkers to predict patient response to immunotherapies.
Overall: PositiveStrengths
- Improves accuracy and efficiency of pathologists in cancer diagnosis.
- Helps identify biomarkers to predict patient response to immuno-oncology treatments, potentially saving healthcare costs.
- Utilizes AI-driven multimodal tissue analysis, clinical outcomes correlation, and expert-led scientific analysis for reliable data.
- Offers standardized biomarker assessment from preclinical research through late-stage clinical development.
- Can be customized by pathologists without extensive technical background.
- Reduces the risk of human error and enhances the quality of patient care through collaborative AI.
Limitations
- Limited public reviews specifically for Nucleai, making it difficult to gauge widespread user experience.
- The technology is still under development, with initial deployments in hospitals and research centers.
- Challenges exist in providing AI tools with sufficient data for training to identify abnormal cells.
- Ethical considerations, data protection, legal regulations, and privacy are potential drawbacks of AI in healthcare.
- Some AI tools in nuclear medicine have shown variability in performance across subspecialty domains.
Based on reviews from: BioPharm International, Capterra, G2, Gilead Sciences, Grove Ventures, Nature Biomedical Engineering, NucNet, Nucleai, Parsers VC, pharmaphorum, PitchBook, Reddit, Stanford Medicine, The Times of Israel, TrustRadius, Vertex Ventures, YouTube
Last updated: 2026-10-04
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Nucleai
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for Nucleai.
Nucleai Unlocking Spatial Biology
Nucleai
Nucleai Academy: AI Spatial Biomarkers & Diagnostics for Antibody-Drug Conjugates (ADCs)
Nucleai
Nucleai Academy: Spatial AI Biomarkers: The Ideal Companions for Next-Gen Cancer Treatments
Nucleai
Nucleai Demo
Nucleai
Nucleai Academy: From Images to Spatial Biological Features: How Errors Percolate
Nucleai
Frequently Asked Questions
Investors who backed Nucleai
Funded through the company that built this tool.
